Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
Information source: Wyeth
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Breast Cancer
Intervention: HKI-272 (Drug); Placebo (Other); Moxifloxacin (Drug)
Phase: Phase 1
Status: Recruiting
Sponsored by: Wyeth Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth
Overall contact:
Trial Manager, Email: clintrialparticipation@wyeth.com
Summary
The purpose of this study is to determine whether HKI-272 affects the rhythms of the heart
(cardiac repolarization).
Clinical Details
Official title: A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study of the Effects of HKI-272 on Cardiac Repolarization in Healthy Adult Subjects
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Crossover Assignment, Pharmacokinetics/Dynamics Study
Primary outcome: QTc interval
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Men or women of nonchildbearing potential,
- 18-50 years old.
- Healthy as determined by the investigator, including physical examination, laboratory
test results, and medical history.
Locations and Contacts
Trial Manager, Email: clintrialparticipation@wyeth.com
Tacoma, Washington 98418, United States; Recruiting
Additional Information
Starting date: May 2008
Ending date: July 2008
Last updated: July 1, 2008
|
